tiprankstipranks
Lakefront Biotherapeutics (DE:GXEA)
FRANKFURT:GXEA
Germany Market
GXEA
Lakefront Biotherapeutics
RESEARCH TOOLSreports

Lakefront Biotherapeutics (GXEA) Ratios

0 Followers

Lakefront Biotherapeutics Ratios

DE:GXEA's free cash flow for Q2 2026 was €-1.86. For the 2026 fiscal year, DE:GXEA's free cash flow was decreased by € and operating cash flow was €-3.59. See a summary of the company’s cash flow.
Ratios
TTM
Dec 25Dec 24Dec 23Dec 22
Liquidity Ratios
Current Ratio
 32.82 20.15 9.97 9.02 8.11
Quick Ratio
 32.82 20.00 9.81 8.84 8.01
Cash Ratio
 1.93 0.57 0.19 0.39 0.97
Solvency Ratio
 6.91 2.21 0.10 0.16 -0.07
Operating Cash Flow Ratio
 -2.74 -1.68 -0.96 -0.95 -0.96
Short-Term Operating Cash Flow Coverage
 -121.40 0.00 0.00 0.00 0.00
Net Current Asset Value
€ 2.22B€ 2.91B€ 2.10B€ 2.30B€ 2.03B
Leverage Ratios
Debt-to-Assets Ratio
 <0.01 <0.01 <0.01 <0.01 <0.01
Debt-to-Equity Ratio
 <0.01 <0.01 <0.01 <0.01 <0.01
Debt-to-Capital Ratio
 <0.01 <0.01 <0.01 <0.01 <0.01
Long-Term Debt-to-Capital Ratio
 0.00 0.00 0.00 0.00 0.00
Financial Leverage Ratio
 1.03 1.05 1.43 1.56 1.87
Debt Service Coverage Ratio
 351.45 170.31 49.54 25.04 0.36
Interest Coverage Ratio
 0.00 226.16 -206.74 -53.36 -14.32
Debt to Market Cap
 <0.01 0.00 0.00 0.00 0.00
Interest Debt Per Share
 0.09 0.14 0.19 0.17 0.47
Net Debt to EBITDA
 -0.24 -0.23 -1.21 -3.08 -125.57
Profitability Margins
Gross Profit Margin
94.88%97.33%87.35%100.00%100.00%
EBIT Margin
53.84%27.25%-0.79%3.08%-25.57%
EBITDA Margin
54.67%32.27%15.72%21.29%1.60%
Operating Profit Margin
61.57%45.08%-68.33%-36.82%-54.32%
Pretax Profit Margin
58.32%27.05%-1.12%2.35%-29.37%
Net Profit Margin
60.23%28.85%26.88%88.31%-90.36%
Continuous Operations Profit Margin
59.99%28.72%-0.47%-1.66%-29.60%
Net Income Per EBT
103.28%106.65%-2401.36%3763.50%307.68%
EBT Per EBIT
94.71%60.01%1.64%-6.37%54.06%
Return on Assets (ROA)
17.81%9.42%1.79%4.86%-4.60%
Return on Equity (ROE)
19.58%9.92%2.56%7.57%-8.63%
Return on Capital Employed (ROCE)
18.60%15.41%-4.96%-2.25%-3.11%
Return on Invested Capital (ROIC)
18.59%15.40%-2.06%1.59%-3.11%
Return on Tangible Assets
22.95%9.42%1.90%5.09%-4.82%
Earnings Yield
35.00%17.50%4.22%8.73%-8.01%
Efficiency Ratios
Receivables Turnover
 17.60 20.91 5.81 3.65 3.12
Payables Turnover
 0.77 0.91 0.36 0.00 0.00
Inventory Turnover
 0.00 1.32 0.68 0.00 0.00
Fixed Asset Turnover
 0.00 13.79 2.24 1.90 1.56
Asset Turnover
 0.30 0.33 0.07 0.06 0.05
Working Capital Turnover Ratio
 0.38 0.00 0.09 0.07 0.06
Cash Conversion Cycle
 -456.35 -106.86 -424.89 99.97 117.02
Days of Sales Outstanding
 20.73 17.46 62.87 99.97 117.02
Days of Inventory Outstanding
 0.00 276.09 535.96 0.00 0.00
Days of Payables Outstanding
 477.08 400.41 1.02K 0.00 0.00
Operating Cycle
 20.73 293.55 598.82 99.97 117.02
Cash Flow Ratios
Operating Cash Flow Per Share
 -2.62 -3.91 -4.84 -6.16 -7.62
Free Cash Flow Per Share
 -2.68 -4.12 -6.08 -6.45 -8.18
CapEx Per Share
 0.06 0.21 1.24 0.29 0.56
Free Cash Flow to Operating Cash Flow
 1.02 1.05 1.26 1.05 1.07
Dividend Paid and CapEx Coverage Ratio
 -42.13 -18.58 -3.90 -21.06 -13.55
Capital Expenditure Coverage Ratio
 -42.13 -18.58 -3.90 -21.06 -13.55
Operating Cash Flow Coverage Ratio
 -30.32 -37.23 -27.30 -42.31 -22.85
Operating Cash Flow to Sales Ratio
 -0.19 -0.23 -1.16 -1.69 -2.07
Free Cash Flow Yield
-12.95%-14.79%-22.89%-17.54%-19.74%
Valuation Ratios
Price-to-Earnings (P/E) Ratio
 2.56 5.71 23.71 11.45 -12.49
Price-to-Sales (P/S) Ratio
 1.54 1.65 6.37 10.11 11.29
Price-to-Book (P/B) Ratio
 0.52 0.57 0.61 0.87 1.08
Price-to-Free Cash Flow (P/FCF) Ratio
 -7.72 -6.76 -4.37 -5.70 -5.07
Price-to-Operating Cash Flow Ratio
 -8.84 -7.12 -5.49 -5.97 -5.44
Price-to-Earnings Growth (PEG) Ratio
 0.02 0.02 -0.01 -0.12 -0.17
Price-to-Fair Value
 0.52 0.57 0.61 0.87 1.08
Enterprise Value Multiple
 2.58 4.88 39.33 44.43 577.68
Enterprise Value
 1.39B 1.75B 1.70B 2.27B 2.24B
EV to EBITDA
 2.57 4.88 39.33 44.43 577.68
EV to Sales
 1.41 1.58 6.18 9.46 9.27
EV to Free Cash Flow
 -7.07 -6.46 -4.24 -5.33 -4.16
EV to Operating Cash Flow
 -7.23 -6.81 -5.32 -5.59 -4.47
Tangible Book Value Per Share
 34.08 49.09 40.25 39.41 35.16
Shareholders’ Equity Per Share
 44.14 49.10 43.80 42.40 38.45
Tax and Other Ratios
Effective Tax Rate
 -0.03 -0.06 0.58 1.71 >-0.01
Revenue Per Share
 13.44 16.88 4.17 3.64 3.67
Net Income Per Share
 8.09 4.87 1.12 3.21 -3.32
Tax Burden
 1.03 1.07 -24.01 37.64 3.08
Interest Burden
 1.08 0.99 1.42 0.76 1.15
Research & Development to Revenue
 0.24 0.41 1.22 1.01 1.12
SG&A to Revenue
 0.11 0.10 0.35 0.39 0.42
Stock-Based Compensation to Revenue
 0.00 0.02 0.00 0.24 0.37
Income Quality
 -0.32 -0.80 -4.32 -1.92 2.30
Currency in EUR